The subject of this publication is the selective contract “AOK-Priomed Focus Rheuma according to § 140a SGB V” with specialists in general medicine with a valid general practitioner's approval, or specialists in internal medicine, with additional rheumatological qualification and specialists in internal medicine (SP) rheumatology within the framework of a so-called “open-house Model”. All suitable and interested general medical specialists with a valid general practitioner's approval, or specialists in internal medicine with additional rheumatological qualification and specialists in internal medicine, rheumatology and specialists in internal medicine (SP) rheumatology, will be required to specify uniform contractual conditions as well as a uniform access procedure. selective contract offered. Interested specialists in general medicine with a valid general practitioner's approval, or specialists in internal medicine, with additional rheumatological qualification and specialists in internal medicine and (SP) rheumatology can request the participation documents and the contract at the contact address mentioned under I.1). The condition for concluding a contract is that the interested service provider submits the requested participation documents.

The subject of this publication is the selective contract “AOK-Priomed Focus Rheuma according to § 140a SGB V” with specialists in general medicine with a valid general practitioner's approval or specialists in internal medicine, with additional rheumatological qualification and specialists in internal medicine and (SP) rheumatology within the framework of a so-called “open- house model” All suitable and interested service providers with a practical headquarters in Marburg-Biedenkopf (ZIP code: 35037-35719) or in Kassel (postal code 34005-37194) are offered the conclusion of the selective contract, subject to uniform contract conditions and a uniform access procedure. Interested service providers may request the participation documents and the contract from the contact address referred to in I.1. The contract shall be subject to the conclusion of a contract that the interested service provider shall submit the requested participation documents in full and signed. A contract is concluded with each service provider who fulfils the eligibility requirements. There is no exclusivity. The contract may be concluded at any time and under the same conditions. Individual contract negotiations are not carried out. The earliest start of the contract is 1.5.2021. All valid contracts will automatically terminate on 31.12.2024. The latest date for joining the contract is 30.6.2024. The aim of the selective contract is to improve a seamless, timely and targeted care of insured persons with rheumatoid arthritis (RA), spondyloarthritis (SpA), collagenosis and polymyalgia rheumatica through optimal, multidisciplinary and multiprofessional collaboration and the defined treatment path, and by providing a complete, timely and targeted treatment path. high-quality medical treatment to achieve the fastest possible detection and treatment of rheumatoid arthritis (RA), spondyloarthritis (SpA), collagenosis and rheumatic polymyalgia.

The participating doctors regularly take part in the quarterly quality training courses held by the participating rheumatologists on the high-quality care of RA or SpA, collagenoses or polymyalgia rheumatica.

This publication does not constitute the award of a public contract within the meaning of Directive 2014/24/EU or public procurement law. In order to ensure the widest possible level of transparency for the contracts envisaged, publication is made in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual requirements, such as the 'open procedure' method designation or the information under point IV.2.2) 'Closing date for receipt of tenders' or point IV.2.7) 'Conditions for the opening of tenders' are solely due to the use of this notice document and the publication platform. The data provided under point IV.2.2) or point IV.2.7) are therefore to be considered as fictitious information. This does not imfer any further importance, in particular submission to procurement law, insofar as they are not compulsory for legal reasons.